Did you mean: Siddharth KAPadia

[HTML][HTML] Yttrium‐90 radioembolization for the treatment of solitary, unresectable HCC: the LEGACY study

…, E Boucher, K Fowers, R Lewandowski, SA Padia - Hepatology, 2021 - journals.lww.com
Conclusions Despite clear relationships between HBV RNA and HBcrAg levels and CHB
phases, these markers have limited additional value in differentiating CHB phases because of …

90Y radioembolization of colorectal hepatic metastases using glass microspheres: safety and survival outcomes from a 531-patient multicenter study

…, B Boyer, S Kauffman, S Kwan, SA Padia… - Journal of nuclear …, 2016 - Soc Nuclear Med
Hepatic metastases of colorectal carcinoma are a leading cause of cancer-related mortality.
Most colorectal liver metastases become refractory to chemotherapy and biologic agents, at …

Radioembolization with chemotherapy for colorectal liver metastases: a randomized, open-label, international, multicenter, phase III trial

…, MS Johnson, CT Sofocleous, SA Padia… - Journal of Clinical …, 2021 - ascopubs.org
PURPOSE To study the impact of transarterial Yttrium-90 radioembolization (TARE) in
combination with second-line systemic chemotherapy for colorectal liver metastases (CLM). …

Clinical and dosimetric considerations for Y90: recommendations from an international multidisciplinary working group

R Salem, SA Padia, M Lam, J Bell, C Chiesa… - European journal of …, 2019 - Springer
The TheraSphere Global Dosimetry Steering Committee was formed in 2017 by BTG
International to review existing data and address gaps in knowledge related to dosimetry. This …

[PDF][PDF] STANDARDS OF PRACTICE

…, BL Connolly, AM Cahill, TJ Ward, SA Padia… - J Vasc Interv …, 2018 - academia.edu
SIR produces its Standards of Practice documents by using the following process. Topics of
relevance and timeliness are conceptualized by the Standards of Practice Committee …

Safety and efficacy of drug-eluting bead chemoembolization for hepatocellular carcinoma: comparison of small-versus medium-size particles

SA Padia, G Shivaram, S Bastawrous… - Journal of Vascular and …, 2013 - Elsevier
… Author links open overlay panel Siddharth A. Padia MD a , Giri Shivaram MD a , Sarah
Bastawrous DO b , Puneet Bhargava MD b , Nghia J. Vo MD a , Sandeep Vaidya MD a , Karim …

Radioembolization of Hepatic Malignancies: Background, Quality Improvement Guidelines, and Future Directions.

SA Padia, RJ Lewandowski, GE Johnson… - Journal of vascular …, 2016 - europepmc.org
Radioembolization of Hepatic Malignancies: Background, Quality Improvement Guidelines, and
Future Directions. - Abstract - Europe PMC Sign in | Create an account https://orcid.org Europe …

Transcatheter therapy for hepatic malignancy: standardization of terminology and reporting criteria

…, BJ d'Othee, SA Padia… - Journal of vascular …, 2016 - pubmed.ncbi.nlm.nih.gov
… 6 , Siddharth A Padia

[HTML][HTML] Clinical, dosimetric, and reporting considerations for Y-90 glass microspheres in hepatocellular carcinoma: updated 2022 recommendations from an …

R Salem, SA Padia, M Lam, C Chiesa, P Haste… - European Journal of …, 2023 - Springer
Purpose In light of recently published clinical reports and trials, the TheraSphere Global
Dosimetry Steering Committee (DSC) reconvened to review new data and to update previously …

Segmental Yttrium-90 radioembolization versus segmental chemoembolization for localized hepatocellular carcinoma: results of a single-center, retrospective …

SA Padia, GE Johnson, KJ Horton, CR Ingraham… - Journal of Vascular and …, 2017 - Elsevier
Purpose To compare segmental radioembolization with segmental chemoembolization for
localized, unresectable hepatocellular carcinoma (HCC) not amenable to ablation. Materials …
Did you mean to search for: Siddharth KAPadia